Unicycive Therapeutics (Nasdaq: UNCY) announced that the company is scheduled to participate in the 25th Annual Needham Virtual Healthcare Conference. Shalabh Gupta, M.D., Chief Executive Officer, will present on Wednesday, April 15, 2026, at 3:45 p.m. ET.  
  
Unicycive is a B2i Digital Featured Company. See the full profile here: [https://b2idigital.com/unicycive](https://b2idigital.com/unicycive)  
  
A link to the live and archived webcast is available on the Unicycive website under the Investors section: Events and Presentations.  
  
See the press release at [https://ir.unicycive.com/news/detail/121/unicycive-therapeutics-to-present-at-the-25th-annual](https://ir.unicycive.com/news/detail/121/unicycive-therapeutics-to-present-at-the-25th-annual)  
  
Unicycive Therapeutics is a clinical-stage biotechnology company developing novel treatments for kidney diseases. The company’s lead investigational treatment, oxylanthanum carbonate, is a novel phosphate-binding agent for treating hyperphosphatemia in patients with chronic kidney disease who are on dialysis and is currently under review by the U.S. Food and Drug Administration. Its second program, UNI-494, targets conditions related to acute kidney injury and has received FDA orphan drug designation for preventing delayed graft function in kidney transplant patients.  
  
Led by CEO Dr. Shalabh Gupta, MD and a seasoned executive team including CFO John Townsend, EVP Doug Jermasek, EVP Pramod Gupta, Dr. Atul Khare, Ph.D., M.B.A., and Dr. Guru Reddy, Unicycive is committed to addressing unmet needs in kidney disease treatment.  
  
Learn more about Unicycive Therapeutics at [https://ir.unicycive.com](https://ir.unicycive.com) and about other B2i Digital Featured Companies at https://b2idigital.com/featured-companies.  
  
Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted UNCY stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of UNCY or any security, and it is not intended to offer any opinion on UNCY as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete Disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer.

Unicycive Therapeutics (Nasdaq: UNCY) announced that the company is scheduled to participate in the 25th Annual Needham Virtual Healthcare Conference. Shalabh Gupta, M.D., Chief Executive Officer, will present on Wednesday, April 15, 2026, at 3:45 p.m. ET.